These Canadian marijuana stocks are growing faster than the rest
SmallCapPower | May 31, 2017: With relaxed views of marijuana consumption throughout the globe and Canada’s plans to legalize recreational marijuana consumption by next summer, it comes as no surprise that some marijuana companies have experienced tremendous growth. If the industry continues to grow and consumers become more willing to try marijuana for medical or recreational purposes, we could continue to see these high growth rates amongst marijuana companies. Today we have identified four Canadian marijuana stocks that have experienced the highest revenue growth in 2016 out of any company in the industry, as per data from Thomson Reuters.
Related: For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
Aphria Inc. (TSX: APH) – $5.55
Pharmaceuticals
Aphria Inc., formerly Black Sparrow Capital Corp., is a Canada-based company, which is engaged in producing and selling medical marijuana through retail sales and wholesale channels. The Company’s retail sales are sold primarily through the Company’s online store, as well as telephone orders. Its wholesale shipments are sold to other Medical Purposes Regulations (MMPR) Licensed Producers. It offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil.
- Market Cap: $765,991,854
- Total Revenue (LTM): $8,433,930
- Debt to Equity: 0.0%
- YTD Price Change: 10.1%
- Revenue Growth: 1,429%
Emerald Health Therapeutics Inc. (TSXV: EMH) – $1.20
Pharmaceuticals
Emerald Health Therapeutics, Inc., formerly T-Bird Pharma Inc., is a Canada-based company, which through its subsidiary, Emerald Health Botanicals Inc. (Botanicals), is engaged in the production and sale of medical marijuana. The Company’s segment is production and sales of medical marijuana pursuant to the Marijuana for Medical Purposes Regulations. Botanicals produces cannabis oils and capsules.
- Market Cap: $111,744,212
- Total Revenue (LTM): $253,320
- Debt to Equity: 0.0%
- YTD Price Change: -7.7%
- Revenue Growth: 710%
OrganiGram Holdings Inc. (TSXV: OGI) – $2.50
Pharmaceuticals
OrganiGram Holdings Inc., formerly Inform Exploration Corp., is a Canada-based company, which operates through its subsidiary Organigram Inc. Organigram Inc. is a licensed medical marijuana producer as regulated by Health Canada under the Marijuana Medical Access Regulations (MMAR) of the Government of Canada.
- Market Cap: $255,403,532
- Total Revenue (LTM): $6,127,630
- Debt to Equity: 16.9%
- YTD Price Change: -13.8%
- Revenue Growth: 521%
Canopy Growth Corp. (TSX: WEED) – $7.81
Pharmaceuticals
Canopy Growth Corporation, formerly Tweed Marijuana Inc., is a diversified cannabis company. The Company, through its subsidiaries Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) and Tweed Farms Inc. (Tweed Farms), is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan. Tweed is a licensed producer of medical marijuana. Tweed’s commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year.
- Market Cap: $1,291,150,137
- Total Revenue (LTM): $12,699,000
- Debt to Equity: 3.2%
- YTD Price Change: -14.6%
- Revenue Growth: 436%
Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below:
